Comparative Pharmacology
Head-to-head clinical analysis: MYOVIEW versus MYOVIEW 30ML.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOVIEW versus MYOVIEW 30ML.
MYOVIEW vs MYOVIEW 30ML
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myoview (technetium Tc-99m tetrofosmin) is a lipophilic cationic complex that accumulates in myocardial cells via mitochondrial uptake. It is used as a myocardial perfusion imaging agent to assess regional blood flow.
Technetium Tc-99m tetrofosmin is a lipophilic cation that passively diffuses across cell membranes and is retained in viable myocardial tissue via electrostatic binding to mitochondria. Accumulation requires intact mitochondrial function, reflecting myocardial perfusion and viability.
0.08 mg/kg intravenous bolus, maximum 9 mg, followed by saline flush. Imaging within 30-60 minutes post-injection.
0.14 mg/kg (3.7 MBq/kg) intravenously as a single dose for myocardial perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: 4.3–6.1 hours (mean 5.2 hours); clinical context: allows imaging up to 6 hours post-injection with stable myocardial retention
Terminal elimination half-life: 6.5 ± 2.0 hours in patients with normal renal function. Extended to 9.1 hours with moderate renal impairment (creatinine clearance 30–60 mL/min).
Renal: 93% within 24 hours (primarily as unchanged drug); Fecal: 5%; Biliary: negligible
Renal and biliary: approximately 40% renal (glomerular filtration) and 60% fecal within 48 hours.
Category C
Category C
Myocardial Perfusion Imaging Agent
Myocardial Perfusion Imaging Agent